Business
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection\nA single injection of INT230-6 can induce up to >95% necrosis of a tumor\nINT230-6 demonstrated an increase in CD4 T-cells and NK cells within tumors\nGene expression profiling revealed treatment effect of up-regulation of immune pathways expressed by T-cell activation, lymphocyte activation and inflammatory responses \nINT230-6 demonstrated a favorable safety profile and was well tolerated\nPatient interest in the new treatment was high\nSHELTON, Conn., Dec. 8, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that safety, tolerability, efficacy and immune activation data from the company's Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.\n\n \n \n \n \n \n \n\n \nConcurrent Poster Spotlight Session Block #6PS16 Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and BiomarkersModerator: Hope S. Rugo, MD, FASCO, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CaliforniaTitle: Intra-tumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell necrosis and immunomodulatory effects: A phase II randomized window-of-opportunity study – the INVINCIBLE trialPresentation #: PS16-03Date and Time: Friday, December 8, 7:00 – 8:00 a.m. CTLocation: Stars at Night Ballroom 3 & 4Presenter: Angel Arnaout, M.D., MSc, Ottawa Hospital Research Institute, Ontario Institute for Cancer ResearchDiscussant: Sangeetha Reddy, M.D., M.S.C.I., UT Southwestern Medical Center, Dallas, Texas\nCopies of the presentation materials are available on Intensity's website on the publications, papers and posters page.\n\"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are imm...